Literature DB >> 1295443

p53 mutation in human nasopharyngeal carcinomas.

K W Lo1, C H Mok, D P Huang, Y X Liu, P H Choi, J C Lee, S W Tsao.   

Abstract

Nasopharyngeal carcinoma (NPC) is the third most common cancer in the southern provinces of China, but a rare cancer in other parts of the world. Epidemiological studies suggested a multifactorial etiology of NPC involving infection of Epstein Barr virus (EBV), genetic predisposition, environmental factors, such as consumption of salted fish, and other unknown factors. p53 mutation is a common event in many forms of human cancers but its possible involvement in the pathogenesis of NPC has not been examined. The presence of p53 mutation in NPC is studied by the sensitive PCR-SSCP analysis and direct DNA sequencing method. The frequent sites of p53 mutation (exons 4 to 8) reported in other human tumors were studied. Thirty-eight biopsied tumors of NPC and 4 NPC cell lines were examined for the presence of p53 mutation. No mutation of p53 resulting in change in amino acid sequence of the encoded p53 protein was identified in any of the biopsies tumors. RFLP studies of the biopsied materials of NPC also revealed no loss of heterozygosity at chromosome region 17p13 in 15 out of 15 informative cases, which further supports the conclusion that p53 mutation is an infrequent event in NPC. Apparently, p53 mutation has no significant role in the pathogenesis of this special group of human cancers. However, p53 mutation is frequently observed in cell lines derived from the primary NPC tumors. All the three NPC cell lines examined carry a missense p53 mutation, suggesting that mutation of the p53 gene may confer growth advantage to the tumor cells to become established in culture.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1295443

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

2.  Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.

Authors:  Yock Ping Chow; Lu Ping Tan; San Jiun Chai; Norazlin Abdul Aziz; Siew Woh Choo; Paul Vey Hong Lim; Rajadurai Pathmanathan; Noor Kaslina Mohd Kornain; Chee Lun Lum; Kin Choo Pua; Yoke Yeow Yap; Tee Yong Tan; Soo Hwang Teo; Alan Soo-Beng Khoo; Vyomesh Patel
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

3.  Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.

Authors:  K L Fries; W E Miller; N Raab-Traub
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 4.  Locally advanced nasopharyngeal cancer.

Authors:  J F Ensley; E Youssef; H Kim; G Yoo
Journal:  Curr Treat Options Oncol       Date:  2001-02

5.  The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection.

Authors:  Can Guo; Zhi-Gang Pan; Da-Jiang Li; Jing-Ping Yun; Mei-Zhen Zheng; Zhe-Yu Hu; Li-Zhen Cheng; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2006-05-29       Impact factor: 5.531

6.  Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma.

Authors:  A Jayasurya; B H Bay; W M Yap; N G Tan
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

7.  The uS8, uS4, eS31, and uL14 Ribosomal Protein Genes Are Dysregulated in Nasopharyngeal Carcinoma Cell Lines.

Authors:  Edmund Ui-Hang Sim; Kher-Lee Ng; Choon-Weng Lee; Kumaran Narayanan
Journal:  Biomed Res Int       Date:  2017-07-16       Impact factor: 3.411

8.  TRIM21-SERPINB5 aids GMPS repression to protect nasopharyngeal carcinoma cells from radiation-induced apoptosis.

Authors:  Panpan Zhang; Xiaomin Li; Qiuping He; Lulu Zhang; Keqing Song; Xiaojing Yang; Qingmei He; Yaqin Wang; Xiaohong Hong; Jun Ma; Na Liu
Journal:  J Biomed Sci       Date:  2020-01-31       Impact factor: 8.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.